BHWM
VIR icon

Beaird Harris Wealth Management’s Vir Biotechnology VIR Stock Holding History

Beaird Harris Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28
Closed -$1K – 777
2022
Q3 		$1K Hold
28
– – ﹤0.01% 470
2022
Q2 		$1K Hold
28
– – ﹤0.01% 389
2022
Q1 		$1K Hold
28
– – ﹤0.01% 584
2021
Q4 		$1K Buy
+28
New +$1.1K ﹤0.01% 631

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Beaird Harris Wealth Management's VIR Position: Q4 2022 in Review

Beaird Harris Wealth Management sold out of Vir Biotechnology (VIR) in Q4 2022, closing a stake of 28 shares — an estimated $1K sold.

Beaird Harris Wealth Management first reported a position in VIR in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q3 2022. 223 funds tracked by Wall St. Rank hold VIR as of Q4 2022.

  • Beaird Harris Wealth Management reported no remaining Vir Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Beaird Harris Wealth Management sold 28 Vir Biotechnology shares in Q4 2022, an estimated $1K.
  • Beaird Harris Wealth Management first reported a position in Vir Biotechnology in Q4 2021 and held it in 4 quarters.
  • Beaird Harris Wealth Management's Vir Biotechnology position peaked at $1K in Q3 2022.
  • 223 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2022.

Based on Beaird Harris Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.